Orion Stock: Q2 Revenue Is Already Public, So I Counted It

Almost every listed company I follow tells me how it did four times a year. Orion stock is attached to a company that tells me twelve times a year, and that single habit changed how I approach the name. Orion Corporation, the Korean confectionery maker behind Choco Pie, publishes sales and operating profit for each of its national subsidiaries every month. Korea, China, Vietnam and Russia each get their own line, every thirty days.

For a US investor this is unusual enough to be worth pausing on. When Mondelez or Hershey report, the quarter arrives as one sealed envelope. With Orion, by the time the quarterly envelope shows up, I have already read two thirds of what is inside it. So rather than wait for the second quarter print, I sat down and rebuilt the quarter myself from the monthly filings. What follows is that reconstruction, what it says about where the growth actually comes from, and the one number I still cannot see.

Where I landed, before the detail.
· Cumulative net sales through June came to 1.8343 trillion won, roughly $1.28 billion, of which the three overseas units account for 68.2%.
· Subtracting first quarter figures leaves second quarter consolidated revenue of about 895.1 billion won, roughly $626 million, which sits 0.2% from the published consensus.
· That leaves margin as the only live variable. Consensus implies 89.7 billion won, roughly $62.7 million, of operating profit across April and May.
· The fastest profit growth in the group is not in China. In the first quarter Russia grew operating profit 66.2% against China’s 42.7%.
· Shares closed at 133,800 won, about $93.58, on Monday, August 3, 2026, for a market value near $3.70 billion.

Contents16 min read

First I checked that the method works

Before trusting a reconstruction I want proof the inputs add up to something the market already accepts. Korean press reporting on July 13, 2026 carried the June subsidiary numbers: Russia 34.9 billion won in net sales with 4.6 billion won of operating profit, China 124.0 billion won and 20.7 billion won, Vietnam 38.4 billion won and 4.9 billion won, Korea 98.5 billion won and 12.1 billion won.

Add the four sales lines and I get 295.8 billion won for June. Add the four profit lines and I get 42.3 billion won. Two days later, on July 15, 2026, a Korean sell-side analyst at KB Securities published a note quoting June revenue of 295.8 billion won and June operating profit of 42.3 billion won. Both figures match my addition exactly, to the last digit.

That tells me two things. The monthly disclosures are the consolidated numbers rather than some parallel management measure, and professional analysts are already working from them. Anyone can do this arithmetic. Very few people bother.

The contrast inside the same sector is what makes the habit worth paying for. Nongshim reports its first-quarter overseas revenue country by country and publishes no profit line beside any of it. Revenue grew ₩41.1bn year on year and operating profit grew ₩11.4bn, a 27.7% incremental margin against a 7.22% consolidated margin in the same quarter, and no filing says which of those seven countries produced it. What Orion’s monthly subsidiary disclosures buy is not diligence. It is the ability to check the arithmetic.

Rebuilding the quarter that Orion stock has not yet reported

Cumulative June figures come from the Korean press summary of the company’s monthly disclosures dated July 13, 2026. First quarter subsidiary figures come from Korean coverage of the first quarter results on May 18, 2026. Shares and combined totals are my own additions from the table values. The India unit, which posted 9.8 billion won of first quarter sales, is not in this set. Subsidiary sums run ahead of the consolidated figures because intercompany eliminations have not been applied: reported first quarter consolidated revenue was 930.4 billion won and consolidated operating profit 165.5 billion won, lower by 4.5 billion won and 3.7 billion won respectively.

Now the arithmetic. Cumulative sales through June across the four units come to 1,834.3 billion won. First quarter across the same four units came to 934.9 billion won. The difference, 899.4 billion won, is the second quarter. Applying the same 0.48% elimination gap that appeared in the first quarter gives consolidated second quarter revenue of roughly 895.1 billion won, about $626 million.

Korean market data provider FnGuide’s consensus, as reported on August 3, 2026, put second quarter consolidated revenue at 897.0 billion won, a 15.4% increase. My reconstruction differs by 1.9 billion won, or 0.2%. At the subsidiary level the agreement is tighter still: subtracting first quarter Russia from the cumulative line gives 105.0 billion won for Russia in the second quarter, and the reported consensus figure for Russia in the second quarter is also 105.0 billion won.

So the revenue line in this print carries essentially no information I do not already have. The company published it in three installments and the consensus absorbed it. Whatever surprise exists is in profitability.

The number I still cannot see

Consensus operating profit for the second quarter is 132.0 billion won, about $92.3 million, up 16%. June is known at 42.3 billion won. That requires 89.7 billion won, roughly $62.7 million, across April and May, or an average of 44.9 billion won a month. First quarter operating profit averaged 55.2 billion won a month (165.5 billion won divided by three, my calculation). Consensus is therefore carrying an assumption that early second quarter profitability ran about 19% below the first quarter.

There are reasons that assumption might hold. Korean reporting on June 17, 2026 described the domestic business in May as down 3% in sales and down 24% in operating profit, with cost of goods rising two percentage points on higher potato, cocoa and egg prices, plus a receivables dispute limiting deliveries and hypermarket store closures. In Vietnam the pressure is competitive rather than input driven. Korean coverage on July 13, 2026 reported that Frito-Lay expanded its Hanoi plant, increased pack weights in potato and rice snacks by 20% and ran heavy discounting, and that Orion’s snack category took the hit. Vietnam second quarter sales work out to 116.4 billion won from the cumulative line, below the 151.3 billion won it did in the first quarter.

So when the print lands, the headline I will skip is revenue. The line I will go straight to is the April and May operating profit, and whether it clears 89.7 billion won. Below that, the domestic cost problem and the Vietnamese discount war are structural rather than seasonal.

Orion stock is priced on China, but Russia is doing the work

The consensus story on this company is a Chinese recovery. The KB Securities note I referenced above frames it that way, expecting growth to continue centered on China, and on size alone that is fair. China is the largest single unit at 42.9% of first half sales. On rate of change, though, the ranking inverts.

First quarter operating profit growth ran Russia 66.2%, China 42.7%, Vietnam 25.2%, Korea 4.6%. In the June month alone Russian operating profit rose 64.3% against China’s 33.5%. Russian net sales that month grew 42.4%, so profit growth outran sales growth by 21.9 percentage points on my calculation. Margin is thickening as the unit scales, which is a different and better condition than volume growth alone.

The mix shift shows up in the annual figures as well. Russian revenue went from 230.5 billion won in 2024 to 339.4 billion won in 2025, a 47.3% increase, and the unit’s share of consolidated revenue rose from 7.4% to 10.2%. Those two numbers imply 2025 consolidated revenue of 3.3275 trillion won, which sits under 0.2% away from the 3.3324 trillion won that Korean market data carries for the same year. Two independent sources point at the same place.

I want to be careful about how I hold this. A rising Russian contribution is a growth story and a concentration risk written with the same pen. It means more of the earnings base sits inside a sanctions environment with ruble translation attached. The company disclosed on July 1, 2026 that its capital program includes 240.0 billion won for a second production building at Tver, and Korean reporting put that project at 11% complete as of May while existing Russian capacity runs above 100% utilization. Until that building opens, Russian growth is capped by physical capacity, and today’s margin may be the best this configuration produces rather than a run rate.

Tver is one line in a larger program. The same July 1, 2026 disclosure put total committed capital spending at 830.0 billion won, roughly $580 million, split across an integrated center at Jincheon in Korea at 460.0 billion won and targeted for completion in 2027, a third Hanoi plant in Vietnam at 130.0 billion won, and the Tver building. Completion rates as of May stood at 36%, 57% and 11% respectively. What that spread tells me is that the capacity constraint I described in Russia is the most binding of the three and the furthest from relief, while Vietnam, the market currently under discount attack, gets new capacity soonest.

There is a second detail in that disclosure that a US reader can verify without a data terminal. Orion has been placing product into Western retail directly rather than only through Asian grocery channels, listing Walmart, Costco, Target and Albertsons in North America, and roughly 1,200 Carrefour locations plus several hundred Morrisons, Sainsbury’s and Spar stores across Europe. None of that shows up as a meaningful revenue line yet, and I am not modeling it. I note it because it is the cheapest piece of due diligence available on this company: the next time I am in a Costco I can look at the shelf and see whether the distribution the company describes actually exists at the store level. That is a checkable claim, and checkable claims are worth more to me than a management target such as the five trillion won revenue ambition the company has also floated without a date attached.

What the group announces and what Orion stock receives

One structural detail matters before anyone buys this. There are two Orion tickers on the Korea Exchange. Orion Holdings trades under 001800 and Orion Corporation, the operating confectionery business, trades under 271560. Nearly all corporate news arrives under the group name, so the announcements and the ticker do not line up automatically.

Two examples from this summer make the point. On June 16, 2026 the group resolved to cancel its entire treasury holding, executed on June 23, and Korean press put the size at 67.5 billion won, about $47.2 million. The breakdown in that same reporting shows 2,488,770 shares at Orion Holdings and 7,344 shares at Orion Corporation. Against 39,528,839 shares outstanding at the operating company, that cancellation is 0.0186% by my calculation. As a holder of 271560, I received effectively nothing from a headline that sounded material. The same gap opens inside a consolidated income statement. Kolmar Korea books 168.2 billion won of consolidated net income, yet the per-share figure the vendor screens treat as canonical is 5,297.77 won rather than the 7,125.6 won simple division gives. The difference belongs to someone else.

The interim dividend runs the other way. The group announced its first interim dividend in company history on July 6, 2026, totaling 102.3 billion won, and Korean coverage of the announcement assigns 69.2 billion won of that to Orion Corporation and 33.1 billion won to Orion Holdings. So 67.6% of the group headline belongs to the operating ticker, which works out to roughly 1,750 won per share, about $1.22, exactly half of the 3,500 won paid for fiscal 2025. Record date was July 21, 2026 and the payment date for Orion Corporation is August 6, 2026.

Same three word phrase in both press releases, opposite economics for me. This is a pattern I have run into before in Korean holdco structures, including when I worked through why Hyosung trades at a third of its stake value, and it is why I compared this cancellation against brokerages that retired a third of their shares outright to calibrate the scale.

Sometimes the split is not the subject but the basis. CJ CheilJedang reports the same first quarter revenue two ways — 7.1111 trillion won on a consolidated basis and 4.0271 trillion won excluding CJ Logistics — and operating profit splits 238.1 billion against 148.5 billion the same way. Depending on which denominator you take, the price to sales ratio reads 0.11 or 0.17, and the screen always prints the first one. I worked through what happens when the multiple has no denominator at all in that name. Counting whose headline it is and asking what the denominator holds are two faces of the same habit.

What Orion stock costs against global confectionery

Orion figures are Korean market data as of the Monday, August 3, 2026 close, with the vendor multiple calculated off a 133,500 won reference price; recomputed at the 133,800 won close the ratios are 13.82 and 1.39. Peer figures come from Mondelez and Hershey pages dated the same session. Won to dollar conversions throughout use 1,429.8 won per dollar.

Orion’s 13.8 times trailing earnings is 60.5% of Mondelez and 57.8% of Hershey on my calculation, and the price to sales line in the table repeats the pattern. On forward earnings the American pair compress toward each other, Mondelez at 19.29 times and Hershey at 18.87, which is the market saying it expects both to earn more next year than they did last year.

The usual explanation for a gap like this is that the cheap company is shrinking. That does not survive contact with the numbers here. Orion grew first quarter consolidated revenue 16% and consolidated operating profit 26%. Its overseas units posted double digit sales growth in three of four markets. The American peers carry richer multiples with dividend yields near 3.2%, which is what mature staples get paid for, while Orion yields 2.6% and grows considerably faster. The gap is not being set by earnings direction. It is being set by listing venue, index membership and the discount Korean equities carry as a class. I ran into the same structural discount from the other direction earlier this summer with a Korean food exporter whose overseas volumes were growing while the multiple sat still, which is why I now treat the Korean listing itself as one of the inputs rather than as background.

Korea’s main board, the KOSPI, is where 271560 trades. It is the senior of Korea’s two exchanges, roughly analogous to the NYSE in domestic standing, with the KOSDAQ sitting alongside it for smaller and growth names.

Four brokers, four numbers, and a reading error to avoid

These are the valuations each Korean house published, cited as fact. I have adopted none of them as my own. Percentages against the close are my calculation.

Reading that table top to bottom, the numbers climb while the dates run backward, which makes it look like a house steadily marking the company down over four months. That reading would be wrong. Four different firms produced four independent estimates; this is a spread across the street, not a trajectory. The most recent of the four, KB Securities, actually raised its number from 150,000 won to 160,000 won and attributed the change to lifting its target multiple from 13 times to 14 times. Stacking separate observers vertically and reading a trend into them manufactures a story nobody told.

What I left out of the price entirely

Orion acquired control of LigaChem Biosciences in 2024 and disclosed on July 24, 2026 that it would put a further 125.0 billion won, about $87.4 million, into the company through affiliate PAN ORION, lifting its stake to 25.53%. Korean business press reporting on that deal lays out the biotech’s losses: an operating loss of 20.9 billion won in 2024, 106.5 billion won in 2025, and 37.4 billion won in the first quarter of 2026. The 2025 figure is roughly five times the prior year. Cash and equivalents fell from 98.6 billion won at the end of 2025 to 63.5 billion won at the end of the first quarter.

The same reporting raises the concern that cash generated in confectionery could underwrite drug development uncertainty for years, with research spending rising as late stage trials expand. The company has said it has no further investment planned and that the biotech assembled roughly one trillion won of development funding including a 250 billion won national growth fund commitment. I have no ability to handicap a clinical timeline, so I assigned the biotech stake neither a positive nor a negative value in what I paid.

Leaving it out is its own kind of error. If that stake is eventually marked at a large number, I bought this company cheaper than I realized. If the losses start eating consolidated earnings, a negative I declined to model arrives anyway. I carry only the second possibility on my watch list.

How I would actually own Orion stock, and where I stand

Practical matters first, because they decide whether any of this is actionable. I could not confirm a US listed depositary receipt for the confectionery arm, so as far as I can tell these shares exist for a foreign buyer only as the Korean line, 271560 on the Korea Exchange. That requires a brokerage relationship that reaches Korean equities directly rather than through a US ticker; the large global brokers that offer international market access generally do, most US discount platforms do not. At the August 3, 2026 close a single share runs about $93.58, and Korea applies a daily price limit of plus or minus 30% on the main board, which changes how a stop behaves compared with a US listing. Broad Korea funds are the indirect route, though I have not verified whether this specific name sits inside the country ETFs that US investors typically use, and I would rather say that plainly than guess at a weight.

My position is small and it is new. I moved this from watch list to a starter holding. The combination that got me there was a company clearing every screen I run on profitability and balance sheet, trading at 13.8 times earnings, generating 68.2% of sales outside its home market, paying its first interim dividend, and down 8.4% over three months. Over twelve months the shares are up 17.4% and over six months up 21.8%, sitting 10.9% below the 250 day intraday high of 150,100 won and 35.2% above the 99,000 won low. Whichever window I quote changes the mood of the sentence, so I am putting all four in one place.

I held this company in the wrong mental folder for years, filed under domestic Korean snacks, and never opened it. Building the subsidiary table is what finally made the 31.8% domestic share land. A bad label keeps a cheap stock invisible.

Two conditions would make me add. The confirmed second quarter shows April and May operating profit at or above 89.7 billion won, which would mark the domestic cost problem as a single quarter event. And Russian operating margin holds alongside sales growth, which would say the pre-expansion capacity ceiling was not the margin peak. One without the other does not move me.

My thesis breaks like this. If both conditions clear and the multiple stays where it is, then the market is treating this geographic spread as concentration risk in Russia and Vietnam rather than as diversification. In that case my premise, that the mix eventually earns a rerating, was wrong from the start, and I close the starter position and go back to watching.

A note I am leaving for myself

When the second quarter statement is filed, I want to arrive with my questions already written rather than react to whatever the headline emphasizes. So, for the version of me reading this later: skip the revenue line, it was published in three monthly installments and you already reconstructed it at 895.1 billion won. Go to April and May operating profit and check it against 89.7 billion won. Then open the Korean subsidiary detail and see whether the 24% May profit decline narrowed or deepened. Then check whether Russian margin survived running a plant above full utilization. Do not read the four broker valuations as a trend, because they never were one. And whatever the biotech line does, remember you deliberately paid nothing for it, which means you are not entitled to count it as a win if it goes right.

Prices and multiples in this piece reflect the Monday, August 3, 2026 close as I checked it while writing. Publication may follow by some days, so live quotes will differ. The Korean won is the reference currency here and dollar figures are approximate conversions at 1,429.8 won per dollar, the rate I last confirmed for that session. Subsidiary results come from Korean media summaries of the company’s monthly disclosures, ratios come from Korean market data, and anything I describe as my calculation is a figure I derived rather than one that appeared in a source. Cash flow and EBITDA fields in that market data set did not reconcile with reported revenue and operating profit under any unit convention, so I excluded them.